Stock Track | Hims & Hers Health Inc (HIMS) Plunges 5.12% Pre-market on Eli Lilly's Weight Loss Drug Relief

Stock Track12-20 17:52

Hims & Hers Health Inc, a telehealth company, saw its stock tumble 5.12% in pre-market trading on Friday. This plunge is likely due to news that Eli Lilly's weight loss drug Zepbound is no longer in shortage, according to the Food and Drug Administration (FDA).

The news poses a major threat to compounding pharmaceutical companies like Hims & Hers that have been selling knockoff versions of Eli Lilly's popular weight loss drug. Hims & Hers specifically makes a compounded version of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy drugs.

The FDA has given compounders until February or March 2025 to wind down their operations involving tirzepatide, the active ingredient in Zepbound. This wind-down period aims to avoid disrupting patient treatment, but it still signals a potential decline in revenue for companies like Hims & Hers that have been benefiting from the shortage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121651221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121651221","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Inc (HIMS) Plunges 5.12% Pre-market on Eli Lilly's Weight Loss Drug Relief","media":"Stock Track","content":"<p>Hims & Hers Health Inc, a telehealth company, saw its stock tumble 5.12% in pre-market trading on Friday. This plunge is likely due to news that Eli Lilly's weight loss drug Zepbound is no longer in shortage, according to the Food and Drug Administration (FDA).</p>\n\n<p>The news poses a major threat to compounding pharmaceutical companies like Hims & Hers that have been selling knockoff versions of Eli Lilly's popular weight loss drug. Hims & Hers specifically makes a compounded version of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy drugs.</p>\n\n<p>The FDA has given compounders until February or March 2025 to wind down their operations involving tirzepatide, the active ingredient in Zepbound. This wind-down period aims to avoid disrupting patient treatment, but it still signals a potential decline in revenue for companies like Hims & Hers that have been benefiting from the shortage.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Inc (HIMS) Plunges 5.12% Pre-market on Eli Lilly's Weight Loss Drug Relief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Inc (HIMS) Plunges 5.12% Pre-market on Eli Lilly's Weight Loss Drug Relief\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-20 17:52 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims & Hers Health Inc, a telehealth company, saw its stock tumble 5.12% in pre-market trading on Friday. This plunge is likely due to news that Eli Lilly's weight loss drug Zepbound is no longer in ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1121651221","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121651221","pubTimestamp":1734688334,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc, a telehealth company, saw its stock tumble 5.12% in pre-market trading on Friday. This plunge is likely due to news that Eli Lilly's weight loss drug Zepbound is no longer in shortage, according to the Food and Drug Administration .The news poses a major threat to compounding pharmaceutical companies like Hims & Hers that have been selling knockoff versions of Eli Lilly's popular weight loss drug. Hims & Hers specifically makes a compounded version of semaglutide, the act","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票轨迹Hims&Hers Health Inc(HIMS)因礼来公司减肥药缓解而盘前暴跌5.12%","themeId":"2f2f105c7e0211c1363da017fa7bc417","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc, a telehealth company, saw its stock tumble 5.12% in pre-market trading on Friday. This plunge is likely due to news that Eli Lilly's weight loss drug Zepbound is no longer in shortage, according to the Food and Drug Administration (FDA).\nThe news poses a major threat to compounding pharmaceutical companies like Hims & Hers that have been selling knockoff versions of Eli Lilly's popular weight loss drug. Hims & Hers specifically makes a compounded version of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy drugs.\nThe FDA has given compounders until February or March 2025 to wind down their operations involving tirzepatide, the active ingredient in Zepbound. This wind-down period aims to avoid disrupting patient treatment, but it still signals a potential decline in revenue for companies like Hims & Hers that have been benefiting from the shortage.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121651221"}